{
 "drug": "Etravirine Tablet",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "04/28/2026",
 "dayN": 119,
 "cat": "Antiviral",
 "companies": [
  "Janssen Research and Development"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "04/28/2026",
   "update_type": "New",
   "initial_posting_date": "04/28/2026",
   "package_ndc": "10147-0570-1",
   "generic_name": "Etravirine Tablet",
   "contact_info": "800-526-7736",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA022187"
    ],
    "brand_name": [
     "ETRAVIRINE"
    ],
    "generic_name": [
     "ETRAVIRINE"
    ],
    "manufacturer_name": [
     "Patriot Pharmaceuticals"
    ],
    "product_ndc": [
     "10147-0570",
     "10147-0571"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "ETRAVIRINE"
    ],
    "rxcui": [
     "754761",
     "1052658"
    ],
    "spl_id": [
     "31cddc7a-0154-c49a-e063-6394a90a1a49"
    ],
    "spl_set_id": [
     "50ca19cb-0f43-4d7b-8c9e-8b3aaded0546"
    ],
    "package_ndc": [
     "10147-0570-1",
     "10147-0571-1"
    ],
    "nui": [
     "N0000175463",
     "N0000175460",
     "N0000009948",
     "N0000190118",
     "N0000185504",
     "N0000182140",
     "N0000185503"
    ],
    "pharm_class_epc": [
     "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]",
     "Cytochrome P450 3A Inducers [MoA]",
     "Cytochrome P450 2C9 Inhibitors [MoA]",
     "Cytochrome P450 2C19 Inhibitors [MoA]",
     "P-Glycoprotein Inhibitors [MoA]"
    ],
    "unii": [
     "0C50HW4FO1"
    ]
   },
   "update_date": "04/28/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Etravirine, Tablet, 100 mg (NDC 10147-0570-1)",
   "company_name": "Janssen Research and Development",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "04/28/2026",
   "update_type": "New",
   "initial_posting_date": "04/28/2026",
   "package_ndc": "59676-570-01",
   "generic_name": "Etravirine Tablet",
   "contact_info": "800-526-7736",
   "related_info": "Discontinuation of the manufacture of the drug",
   "openfda": {
    "application_number": [
     "NDA022187"
    ],
    "brand_name": [
     "INTELENCE"
    ],
    "generic_name": [
     "ETRAVIRINE"
    ],
    "manufacturer_name": [
     "Janssen Products LP"
    ],
    "product_ndc": [
     "59676-570",
     "59676-571",
     "59676-572"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "ETRAVIRINE"
    ],
    "rxcui": [
     "754761",
     "758555",
     "1052658",
     "1052660",
     "1250721",
     "1250723"
    ],
    "spl_id": [
     "02fc6f4f-330d-b32e-e063-6294a90a028a"
    ],
    "spl_set_id": [
     "6a9cbc29-9f15-4b24-8d86-206b82887f3d"
    ],
    "package_ndc": [
     "59676-570-01",
     "59676-571-01",
     "59676-572-01"
    ],
    "nui": [
     "N0000175463",
     "N0000175460",
     "N0000009948",
     "N0000190118",
     "N0000185504",
     "N0000182140",
     "N0000185503"
    ],
    "pharm_class_epc": [
     "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]",
     "Cytochrome P450 3A Inducers [MoA]",
     "Cytochrome P450 2C9 Inhibitors [MoA]",
     "Cytochrome P450 2C19 Inhibitors [MoA]",
     "P-Glycoprotein Inhibitors [MoA]"
    ],
    "unii": [
     "0C50HW4FO1"
    ]
   },
   "update_date": "04/28/2026",
   "therapeutic_category": [
    "Antiviral"
   ],
   "dosage_form": "Tablet",
   "presentation": "Intelence, Tablet, 100 mg (NDC 59676-570-01)",
   "company_name": "Janssen Research and Development",
   "status": "To Be Discontinued"
  }
 ]
}